A Study of DPC 817 in HIV-Infected Males
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV, Phase I
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are HIV positive Are male and are between 18 years of age (or the legal age of consent, whichever is older) and 55 years of age Are female and are between 18 years of age (or the legal age of consent, whichever is older) and 55 years of age and are not able to have children (females may participate in Part B only) Have no clinically significant findings on physical examination or clinical laboratory evaluations Have a CD4-lymphocyte count of 50 or more cells/mm3 Are able and willing to comply with the requirements of this study Exclusion Criteria Patients will not be eligible for this study if they: Have an opportunistic infection characteristic of AIDS Are receiving any approved or experimental HIV drugs. Any previous anti-HIV treatment must be stopped at least 4 weeks before the first dose of study medication Are pregnant or breast-feeding Are enrolled in other experimental drug studies or have recieved other experimental drugs within 30 days before the first dose of study drug Have any disease that causes a problem with absorption of drugs Have active hepatitis Have a history of pancreatitis or peripheral neuropathy Have received radiation therapy or chemotherapy within 30 days before the first dose of study drug Have received treatment with drugs that affect the immune system within 30 days before the first dose of study drug or have received an HIV immunotherapeutic vaccine Have taken prescription or over-the-counter products within 14 days of the first dose of study drug unless approved by the doctor Are unable to comply with the dosing schedule and study procedures
Sites / Locations
- University of North Carolina Hospitals
- 3ClincalResearch Center